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ORIGINAL ARTICLE
Clusterin regulates b-amyloid toxicity via Dickkopf-1-driven
induction of the wnt–PCP–JNK pathway
R Killick1,6, EM Ribe1,6, R Al-Shawi2, B Malik1, C Hooper1, C Fernandes1, R Dobson1, PM Nolan3, A Lourdusamy1, S Furney1, K Lin1,
G Breen1, R Wroe1, AWM To1, K Leroy4, M Causevic1, A Usardi1, M Robinson1, W Noble1, R Williamson1, K Lunnon2, S Kellie5,
CH Reynolds1, C Bazenet1, A Hodges1, J-P Brion4, J Stephenson1, J Paul Simons2 and Simon Lovestone1
Although the mechanism of Ab action in the pathogenesis of Alzheimer’s disease (AD) has remained elusive, it is known to increase
the expression of the antagonist of canonical wnt signalling, Dickkopf-1 (Dkk1), whereas the silencing of Dkk1 blocks Ab
neurotoxicity. We asked if clusterin, known to be regulated by wnt, is part of an Ab/Dkk1 neurotoxic pathway. Knockdown of
clusterin in primary neurons reduced Ab toxicity and DKK1 upregulation and, conversely, Ab increased intracellular clusterin and
decreased clusterin protein secretion, resulting in the p53-dependent induction of DKK1. To further elucidate how the clusterin-
dependent induction of Dkk1 by Ab mediates neurotoxicity, we measured the effects of Ab and Dkk1 protein on whole-genome
expression in primary neurons, finding a common pathway suggestive of activation of wnt–planar cell polarity (PCP)–c-Jun
N-terminal kinase (JNK) signalling leading to the induction of genes including EGR1 (early growth response-1), NAB2 (Ngfi-A-
binding protein-2) and KLF10 (Kru¨ppel-like factor-10) that, when individually silenced, protected against Ab neurotoxicity and/or tau
phosphorylation. Neuronal overexpression of Dkk1 in transgenic mice mimicked this Ab-induced pathway and resulted in age-
dependent increases in tau phosphorylation in hippocampus and cognitive impairment. Furthermore, we show that this Dkk1/wnt–
PCP–JNK pathway is active in an Ab-based mouse model of AD and in AD brain, but not in a tau-based mouse model or in
frontotemporal dementia brain. Thus, we have identified a pathway whereby Ab induces a clusterin/p53/Dkk1/wnt–PCP–JNK
pathway, which drives the upregulation of several genes that mediate the development of AD-like neuropathologies, thereby
providing new mechanistic insights into the action of Ab in neurodegenerative diseases.
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INTRODUCTION
Alzheimer’s disease (AD) is characterised by two neuropathologi-
cal lesions: plaques, composed of aggregated b-amyloid (Ab)
peptides,1 and neurofibrillary tangles, composed of
hyperphosphorylated forms of tau.2 It is widely accepted that
Ab is an initiating factor in the pathological process leading to tau
pathology, a concept encapsulated in the ‘amyloid cascade
hypothesis’ formulated over 20 years ago,3 although the details
of this cascade remain largely unknown.4,5
Wnt signalling has been widely implicated in neurodegenera-
tion.6–13 Canonical wnt/b-catenin signalling promotes cell
survival,14 whereas Ab induces the neuronal expression of the
canonical wnt antagonist, Dickkopf-1 (Dkk1).8 Silencing DKK1
protects against Ab-induced apoptosis and tau phosphorylation,8
and neutralising the Dkk1 protein blocks the deleterious effects of
Ab on synapses.15 Clusterin, the product of CLU, recently identified
by large genome-wide association studies to be a susceptibility
factor for late-onset AD16,17 also promotes cell survival,18 whereas
both Dkk119 and clusterin20 protein levels are increased in
amyloid-based mouse models of AD and clusterin is increased
early in disease in blood in humans.20,21
As both clusterin and Dkk1 are cell survival factors, are
implicated in AD pathogenesis and are regulated by wnt
signaling,8,22,23 we speculated that both lie on a common
pathway, most likely to be the amyloid cascade.
MATERIALS AND METHODS
Primary neuronal cultures
Primary neuronal cultures were generated from Sprague Dawley E18 rat and
C57BL/6J E16 mouse embryos by papain dissociation according to the manu-
facturer’s instructions (Worthington, Lakewood, NJ, USA) and cultured as
described.24
Ab preparation
Ab25-35 and Ab35-25 peptides were solubilised in water at 2mgml
 1 and
incubated at 37 1C for 1 h. Ab1-42 oligomer preparation has been described.
25
siRNA knockdown
Small interfering RNA (siRNA) oligonucleotides were designed as
previously described26 with dTdT 30overhangs and a 50-thiol modification
to the sense strand and coupled to Pen1 as described.27
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Western blotting
Western blotting was performed as previously described.28 Antibodies
were detected using fluorophor conjugates emitting at 680/700 or 800 nm
with an infrared scanner (LI-COR Biosystems, Cambridge, UK). Phosphoe-
pitope immunoreactivity values were divided by non-phospho-dependent
immunoreactivity values and are presented as arbitrary units.
Human samples
Human hippocampal brain samples were obtained from the Medical
Research Council (MRC) London Neurodegeneration Brain Bank (Denmark
Hill, London, UK). Average ages were: Controls, 70.1; AD, 78.4; and
frontotemporal dementia (FTD), 72.3 years. Average post-mortem delays
were: Control, 33.1 h; AD, 35.3 h; and FTD, 18.2 h. Sexes were similarly
distributed among the three groups. The 10 nondemented controls had
either no amyloid or tau pathology or a Braak stage score ofo2. Of the 10
AD cases, 8 had Braak stage scores of 6 and the remaining 2 cases had
Braak scores of 5. Frontotemporal lobar degeneration was the primary
diagnosis for all 10 FTD cases. Frozen tissues were thawed and
homogenised in Trizol and total RNA extracted according to the
manufacturer’s instructions (Invitrogen, Paisley, UK).
Quantitative reverse transcription polymerase chain reaction
(qRT-PCR)
Total RNA (1mg) was reverse transcribed using random hexamers and a
Taqman RT kit (Applied Biosystems, Cheshire, UK) according to the
manufacturer’s instructions. PCR primers were designed using the
Universal Probe Library package (Roche Molecular Biochemicals, Lewes,
UK) for rodent genes and Primer Bank (Harvard.edu) for human genes, and
used in SYBR Green-based PCR reactions performed on a Bio-Rad Dyad
Disciple thermal cycler (Bio-Rad, Bath, UK). Relative quantification of gene
expression between samples was determined using the 2-DDCT method as
described by Livak and Scmittgen.29 Internal control genes used to
normalise for RNA input were HPRT for rodent samples and GAPDH for
human samples. All samples were run in triplicate from three independent
experiments. The mean crossing threshold (CT) values for both the target
and internal control genes in each sample were determined and the
2-DDCT calculations performed. The fold change in the target genes (after
normalising to the internal control gene) were calculated for each sample
and the mean calculated. Statistical significance was determined by one-
way analysis of variance and post hoc t-tests. Data are represented as
normalised fold increases over control samples. For human samples, the
resultant gene expression data are represented as box-and-whisker plots
to show data spread.
Statistical analysis
All routine experiments (for example, cell survival assays and immunblot-
ting) were performed in duplicate or more and repeated a minimum of
three times. Unless otherwise stated, the statistical significance of such
data was determined by one-way analysis of variance with post hoc t-test
or by Student’s t-test, using SPSS or Excel, respectively. Values are given as
mean±s.e.m., unless otherwise stated. Processing and statistical analyses
of microarray and bioinformatics data are described in detail in the
appropriate sections of the Supplementary Information.
RESULTS
The induction of Dkk1 by Ab is neurotoxic and clusterin
dependent
Caricasole et al.8 demonstrated that the Ab peptide fragment,
Ab25-35, induces neuronal expression of the wnt antagonist Dkk1
and that silencing of DKK1 blocks Ab neurotoxicity. Using a
penetrating peptide (Pen1)-coupled siRNA duplex to the CLU
gene, we found that knockdown of clusterin also protects against
20mM Ab25-35-induced neurotoxicity (Figure 1a) and furthermore
prevents the rapid induction of DKK1 expression by Ab (Figure 1b).
Conversely, a 3 h treatment of neurons with Ab25-35 resulted in a
substantial (B3.5-fold) increase in intracellular clusterin protein
with a concomitant 55% decrease in clusterin in the cell medium
(Figure 1c), in line with previous evidence that intracellular
clusterin is pro-apoptotic whereas secreted clusterin is cytopro-
tective.30,31 These acute changes in clusterin protein (within
30min; Figure 1d) occur in the absence of changes in clusterin
expression and are specific to Ab as other stressors had little or
different effects on clusterin. Thus, both ultraviolet (UV) irradiation
(300 Joulesm 2) and the proteasome inhibitor MG132 (20 mM)
caused significant cell death at 24 h but UV had no detectable
effects on clusterin protein, whereas MG132 caused a small
decrease in cellular levels, with no effect on extracellular levels
(data not shown).
Ab and Dkk1 induce a common signalling pathway
To explore this neurotoxic signalling pathway further, we
performed whole-genome expression analyses of primary neuro-
nal cultures following acute treatments with either Ab (20 mM
Ab25-35 for 3 h) or recombinant Dkk1 protein (800 ngml
 1 for 2 h).
Within the two resultant lists of gene independently responsive to
Ab and Dkk1, 2061 genes were common to both. A test for
similarities in ordered gene lists was then performed on the two
lists using the OrderedLists software package (http://www.
bioconductor.org/packages/release/bioc/html/OrderedList.html)
within the Bioconductor R environment. A test of the significance
of their ordering by fold change was performed, and in the top
500 genes a P-value ofr0.000 was obtained (this package returns
values to a maximum of three decimal places). When gene
expression was ranked in this way, we observed that of the top
eight genes, five were common to the two treatments (Table 1), a
finding that a hypergeometric distribution calculation indicates is
very unlikely to have occurred by chance alone (Po2.2e 16).
These observations suggest that Dkk1 mediates the effects of Ab
on gene expression.
Only one of these common genes, CCND1 (cyclin D1), is a
known canonical wnt target,32 with the remaining four encoding
transcription factors: EGR1 (early growth response-1), NAB2 (Ngfi-
A-binding protein-2), KLF10 (Kru¨ppel-like factor-10) and FOS (FBJ
murine osteosarcoma viral oncogene homologue). We confirmed
the induction of these genes by both Ab25-35 and by Dkk1 using
qRT-PCR (Supplementary Figure S1a and 1b).
In these experiments we used Ab25-35 to confirm the observa-
tions of Caricasole et al.8 and also noting data suggesting that this
peptide contains the ‘active’ portion of Ab and has been detected
in human brain.33 However, oligomeric forms of Ab1-42 are widely
accepted to be the physiologically relevant neurotoxic species of
Ab, and we therefore assessed the effects of 3mM oligomeric Ab1-42
(Ab1-42
(olig)), finding that these Ab species also increased the
expression of all five Ab/Dkk1 target genes (Supplementary Figure
S1c) and of DKK1 (Supplementary Figure S1d) and had very similar
effects on clusterin (data not shown). Thus, in our hands, the effects
of Ab25-35 and Ab1-42
(olig) were largely indistinguishable, in agree-
ment with findings from other laboratories.34 The oligomeric nature
of the Ab1-42
(olig) preparation is shown in Supplementary Figure S1e.
Ab-induced gene expression is dependent on p53 and is
necessary and sufficient for neurotoxicity
Investigating the molecular mechanism by which Ab drives gene
expression, we first verified the p53 dependency of DKK1
induction using a small-molecule inhibitor of p53 transcriptional
activity, pifithrin-a. This blocked the Ab1-42
(olig) induction of DKK1
and also of the Ab/Dkk1 target genes EGR1 and FOS (Figure 2a).
Conversely, activating p53 with PRIMA1 induced DKK1 (data not
shown) and target gene expression (Figure 2b). A penetrating
siRNA duplex was then generated to target DKK1. Silencing of
DKK1 in primary rodent neurons also blocked Ab1-42
(olig) induction
of the target genes (data not shown), together confirming that Ab
induction of Dkk1 is p53 dependent,8 and that Ab induction of the
target genes is p53 and Dkk1 dependent.
These data therefore demonstrate a pathway whereby Ab
disrupts the balance between intracellular and extracellular
clusterin, resulting in a cascade of events including p53-
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dependent induction of DKK1 expression followed by increased
expression of a set of genes including the transcription factors
EGR1, NAB2, KLF10 and FOS as well as CCND1. We then investi-
gated the relevance of this pathway to Ab neurotoxicity, generat-
ing Pen1 siRNA duplexes to these genes. First, we pretreated
primary neurons with the DKK1 siRNA or the control duplex as
above and then subsequently with 3 mM Ab1-42
(olig) for up to 72 h
and assessed cell survival. By the live/dead assay, silencing DKK1
afforded almost complete protection from Ab at 24 h (Figure 2c)
and by an assay of nuclear integrity at up to 72 h (Figure 2d).
Similar levels of protection were observed by lactate dehydro-
genase assay (data not shown), confirming Dkk1 is a necessary
mediator of Ab neurotoxicity.
We then individually silenced each of the five genes, treated
with Ab1-42
(olig) and measured cell survival as above. Silencing
NAB2, FOS and CCND1 afforded no protection against Ab, but
silencing EGR1 or KLF10 each gave substantial protection as
measured by the live/dead assay (Figure 3a). Using an assay of
nuclear morphology (Figure 3b), EGR1 gave 80% and KLF10 gave
73% protection at 72 h and both were protective as measured by
lactate dehydrogenase assay (Figure 3c), demonstrating EGR1 and
KLF10 are necessary mediators of Ab-induced neurotoxicity.
We then examined the role of the five genes in another aspect
of neurotoxicity, Ab-induced tau phosphorylation. Neurons were
pretreated with the five siRNA duplexes as above and protein
lysates collected after 4 h Ab1-42
(olig) treatments. Penetrating siRNAs
against KLF10, FOS and CCND1 had little effect on Ab-induced tau
phosphorylation, whereas those against EGR1 or NAB2 significantly
reduced Ab-induced increases in PHF-1 immunoreactivity
(Figure 3d), demonstrating that Egr1 and Nab2 are mediators of
Ab-induced tau phosphorylation at this phosphoepitope. Of note,
Egr1 has been shown to drive tau phosphorylation at the PHF-1
epitope and other sites in rat brain via the activation of p35/cdk5,35
whilst, Nab2 is a regulator of Egr1 activity.36,37
Given that silencing CLU protected against Ab neurotoxicity in
a cell survival assay and also blocked the induction of DKK1
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Figure 1. Ab induction of Dickkopf-1 (Dkk1) is clusterin dependent. (a) Rat primary cortical neurons were treated with Pen1 small interfering
RNA (siRNA) to CLU overnight and subsequently with 20 mM Ab25-35 for 24 and 48h and cell survival determined by the nuclear morphology
assay. Cont, Control. (b) Neurons were treated as in (a), RNA collected after 3 h of Ab treatment and qRT-PCR performed (detailed in
Supplementary Methods). (c) Neurons were treated for 4 h with 20 mM Ab25-35 and culture media and total cell lysates were collected and
immunoblotted for clusterin. Clusterin in cell lysates was normalised to b-actin levels. (d) Neurons were treated with 20 mM Ab25-35 for the
times indicated and immunoblotted as in (c). Error bars in (c) and (d) show s.d. qRT-PCR, quantitative reverse transcription polymerase chain
reaction.
Table 1. Ab and Dkk1 induce a common signalling pathway
Ab treated Dkk1 treated
1 EGR1 EGR1
2 IER2 NAB2
3 NAB2 VCL
4 CCND1 KLF10
5 FOS TIMP1
6 BAIAP2 FOS
7 ATF6B CCND1
8 KLF10 CCL20
9 HNRNPL TUBB6
10 THOC3 RHOQ
Microarray data from Ab25-35-treated (20 mM, 3 h) primary mouse cortical
neurons and Dkk1-treated (800 ngml 1, 2 h) primary rat cortical neurons
were processed (Supplementary Information) and ranked by fold change.
The top 10 genes from each treatment are shown.
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Figure 2. Ab-induced gene expression is dependent on p53 and is necessary and sufficient for neurotoxicity. (a) Rat cortical neurons were
treated with 10 mM pifithrin-a for 18 h as indicated and subsequently with Ab1-42
(olig) (3 mM, 3 h). The expression levels of DKK1 (Dickkopf-1),
EGR1 (early growth response-1) and FOS (FBJ murine osteosarcoma viral oncogene homologue) were determined by qRT-PCR. (b) Neurons
were treated as in (b) using 10 mM PRIMA-1 and then with Ab and qRT-PCR performed. (c) Rat neurons were treated o/n at 7 d.i.c. with control
or Pen1 small interfering RNA (siRNA) to DKK1 (160 nM), and then with 3 mM Ab1-42
(olig) for 24 h and cytotoxicity assayed by the live/dead assay.
Healthy cells are labelled green and dead cells are red. Scale bar¼ 10 mM. (d) Neurons were treated as in (c) and cell survival determined at 24,
48 and 72h by the nuclear morphology assay. d.i.c., days in culture; o/n, over night; qRT-PCR, quantitative reverse transcription polymerase
chain reaction.
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(Figure 1 above), we asked if silencing CLU would also block the
downstream target genes including the identified mediators of
toxicity and increase tau phosphorylation. Rat primaries were
pretreated with the si-control or siCLU and treated next day with
3 mM Ab1-42
(olig) for 3 h, RNA collected and qRT-PCR performed. Ab
induction of DKK1 and all five of the common genes, including
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Figure 3. EGR1 (early growth response-1), KLF10 (Kru¨ppel-like factor-10) and NAB2 (Ngfi-A-binding protein-2) mediate neurotoxicity and tau
phosphorylation. (a) Neurons were treated o/n with Pen1 small interfering RNAs (siRNAs) to EGR1, FOS (FBJ murine osteosarcoma viral oncogene
homologue), KLF10, NAB2, CCND1 (cyclin D1) and then with 3mM Ab1-42
(olig) for 24h and cytotoxicity assayed by the live/dead assay. Protective
effects of siRNAs targeting EGR1 and KLF10 are shown. (b) Neurons were treated as in (a) and cell survival determined by the nuclear morphology
assay up to 72h. Significance values (not shown) for the effect of EGR1 and KLF10 siRNA on cell survival at each time point were r0.01. (c)
Neurons were treated as in (a) and cell survival measured by lactate dehydrogenase (LDH) release. (d) Neurons were treated as in (a) and
subsequently with 3mM Ab1-42
(olig) for 4 h. Total lysates were collected and immunoblotted for phospho-tau using PHF-1. Immunoreactivity values
for PHF-1 were normalised to total tau values; densitometric values are shown in the right. (e) Neurons were treated with Pen1-siCLU or control
Pen1 siRNA and subsequently with 3mM Ab1-42
(olig) for 3 h, RNA collected and qRT-PCR performed for DKK1 and the five Ab/Dkk1 target genes.
o/n, over night; qRT-PCR, quantitative reverse transcription polymerase chain reaction.
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Figure 4. Ab induced gene expression in amyloidopathy, but not tauopathy, brain. (a–d) Expression levels of the five common Ab/Dickkopf-1
(Dkk1)-responsive genes were measured by qRT-PCR in total RNA from: cortex of (a) 12-month-old Tg2576 mice (n¼ 9) and their non-TG
littermate controls (n¼ 7) and (b) 12-month-old hTau mice (n¼ 5) and their non-TG littermate controls (n¼ 5); and from hippocampi of (c)
Alzheimer’s disease (AD; n¼ 10) and age-matched controls (n¼ 9) and (d) frontotemporal dementia (FTD; n¼ 9) and age-matched controls
(n¼ 9). TG, transgenic. Mouse data were normalised to HPRT and human data to GAPDH by the 2-DDCT method. Significance was determined by
one-way analysis of variance (ANOVA) and post hoc t-tests. Data are represented as normalised fold increases over control. Significance values
of gene changes in human samples are given in table (e). Outlier values (between 1.5 and 3 times the interquartile range) and extreme values
(43 times the range) are shown as circles and filled circles, respectively. (e) Dkk1-responsive genes examined in AD hippocampus.
Nonsignificant and omitted genes are shown in grey. (f ) Human brain transcriptome data sets were mined with the top 50 most significant
Dkk1-responsive genes. Significance of Dkk1 gene enrichment in AD in the six brain regions examined by Liang et al.40 are shown.
Significance was determined by asymptotic globaltest (see Supplementary Information for full description). (g) KEGG (Kyoto Encyclopedia of
Genes and Genomes) pathway analysis of human homologues of rat Dkk1-responsive genes. The pathway identifier, name and P-values after
correcting for multiple testing by the method of Benjamini are shown. Pathways in bold have been associated with disease in AD brain
expression data by Huang et al.41 qRT-PCR, quantitative reverse transcription polymerase chain reaction.
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EGR1, NAB2 and KLF10, was significantly blocked by the silencing
of CLU (Figure 3e), substantiating further that CLU lies on the Ab
neurotoxic pathway and is a necessary component of the
signalling cascade.
Ab induced gene expression in amyloidopathy, but not tauopathy,
brain
Moving from rodent primary neurons to in vivo mouse models, we
measured the expression levels of the five common genes in
cortex from amyloid-based (Tg257638) and tau-based (hTau39)
lines and their respective nontransgenic littermates. In Tg2576
mice, four of the five genes were significantly upregulated
(Figure 4a). None were upregulated in hTau mice but FOS was
significantly downregulated (Figure 4b). Moving to humans, we
assessed gene expression in hippocampal tissues from AD and
FTD cases as both feature tau pathology but FTD lacks amyloid
pathology. In AD cases, EGR1, KLF10 and FOS were significantly
(Po0.01) upregulated and CCND1 showed an increased trend
(P¼ 0.083; Figure 4c). None of the genes were altered in FTD
(Figure 4d). Examining a further nine of the neuronal Dkk1-
responsive genes, we found JUND, RHOQ and TNFRSF12A to be
significantly (Po0.05) upregulated and TIMP1 to have an
increased trend (P¼ 0.069) in AD hippocampus (see table in
Figure 4e). We then looked for enrichment of the top 50 most
significantly responsive Dkk1 genes in transcriptomic data sets
from control and AD brain. In a large data set in which data from
several cortical regions had been pooled,42 we found significant
(Po0.001) gene enrichment in AD cases. In data sets from
separate brain regions,40 we found enrichment in AD in all regions
but with greater significance in those regions most affected by
the disease (for example, mid-temporal gyrus; P¼ 0.000015) and
least in a relatively spared region (primary visual cortex P¼ 0.014;
Figure 4f), indicating that Dkk1 contributes to the expression
pattern of genes in the AD brain.
People with Trisomy 21 (Down’s syndrome (DS)) have a high
incidence of dementia almost certainly because of the presence of
an additional copy of the APP gene, resulting in the excess
generation of Ab. This is reflected in the almost invariable
presence of AD pathology in post-mortem brain from people with
DS surviving to mid-life. Interrogating a publically available whole-
genome expression data set from DS brain,43 we found highly
significant enrichment of Dkk1-responsive genes (Po0.0027),
adding further to the evidence that this gene signature is driven
by Ab.
Next, we performed further bioinformatics analyses on the
neuronal Dkk1-responsive genes. Interrogating the Ingenuity
database with the 100 most significant Dkk1-responsive genes,
the top pathway identified contained EGR1, NAB2 and KLF10, the
second CCND1 and FOS, from which EGR1, NAB2 and KLF10 were
absent, indicating the two gene sets may serve separate functions.
We then mapped the genes to a human protein–protein
interaction network and used jActiveModules (Ryan Kelley, UCSD,
USA) to identify sub-networks of interacting proteins that
collectively show significant changes in expression.44 One key
differentially expressed functional module was identified within
which a number of KEGG pathways were significantly over-
represented (Figure 4g). Interestingly, 7 of these top 10 Dkk1-
driven pathways also appear in the top 10 disease-associated
pathways (shown in bold in Figure 4g) identified by Huang et al.41
50
50
1
2
KLF10EGR1 NAB2CCND1
3
0
p < 0.05
p < 0.05 p < 0.05
p < 0.01
N
or
m
a
lis
ed
 m
RN
A
FOS
p < 0.01
4
DKK1 TG
Non-TG littermates
1
2
p < 0.02
 
Im
m
u
n
o
re
a
ct
iv
ity
 (a
rbi
tar
y 
un
its
)
PHF-1
1
2
3
p < 0.05
AT8
0
50
50
AT8
Total
tau
DKK1 TG
Non-TG littermates
0
10
20
30
40
50
60
70
80
90
100
Baseline 24 h
%
 ti
m
e 
fre
ez
in
g p < 0.02
DKK1 TG
Non-TG littermates
0
Non-
TG
Non-
TG
5
10
15
TG
20
N
or
m
a
lis
ed
 m
RN
A
0
2
4
TG
6
pr
ot
ei
n 
(μg
/m
l)
p < 0.01 p < 0.01
8
DKK1
mRNA
Dkk1
protein
TG TGCon Con Con
PHF1
Total
tau
Contextual Fear
Conditioning
Mr
x1000
Figure 5. Transgenic overexpression of Dickkopf-1 (DKK1) induces ‘Ab neurotoxicity pathway genes’, tau phosphorylation and cognitive
deficits. (a) DKK1 expression was determined by qRT-PCR (left bar graph) and enzyme-linked immunosorbent assay (ELISA; (right bar graph) in
temporal cortex of neonatal DKK1 transgenic (TG) mice (n¼ 6) and their non-transgenic (non-TG) littermates (n¼ 5). (b) Neonatal expression of
the five Ab/Dkk1 genes determined by qRT-PCR. (c) Immunoblots of hippocampal lysates from 18- to 24-month-old DKK1 TG (n¼ 7) and non-
TG (n¼ 7) mice using antibodies AT8 and PHF-1. Phosphoimmunoreactivity values were normalised to total tau values, within blot (bar charts,
right). (d) The 14–16-month-old Dkk1 TG (n¼ 17) and non-TG littermates (n¼ 16) were subjected to contextual fear conditioning. Time spent
freezing upon placement in the conditioning apparatus at baseline and at 24 h after training are shown. qRT-PCR, quantitative reverse
transcription polymerase chain reaction.
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in human AD brain expression data, indicating Dkk1 affects cell
signalling in the AD brain.
Transgenic overexpression of DKK1 induces ‘Ab neurotoxicity
pathway genes’, tau phosphorylation and cognitive deficits
To model pathway activation downstream of Ab we generated
transgenic mice overexpressing murine Dkk1 in neurons. DKK1
transgenics had increased expression of Dkk1 (Figure 5a) and of
the five common Ab/Dkk1 genes in neonatal temporal cortex
(Figure 5b). Examining tau phosphorylation in mice aged 20 to 25
months, we found a significant increase in hippocampus with AT8
and PHF-1 (Figure 5c), antibodies recognising phospho-tau
epitopes increased in AD.45 Minor and nonsignificant increase in
tau phosphorylation was observed at these epitopes from 6 to 9
months of age. To determine the effects on cognition, contextual
fear conditioning was used as a measure of amygdala- and
hippocampal-dependent memory recall. In young adults, no
significant differences were observed. However, in older animals
(14–16 months), significant (Po0.02) impairment in memory recall
was observed in DKK1 transgenics compared with their littermate
controls (Figure 5d). Thus, it appears that chronic overexpression
of Dkk1 in brain leads to an age-dependent increase in tau
phosphorylation and the appearance of cognitive deficits.
The Ab neurotoxicity pathway is the wnt–planar cell polarity
pathway
Having determined that Ab induction of DKK1 is dependent upon
a rapid effect on clusterin protein and that Dkk1 then drives the
expression of genes mediating key AD-like pathologies in primary
neurons and mouse models and would also appear to affect the
transcriptome and signalling pathways active in the AD brain, we
began to determine in more detail the mechanism by which Dkk1
drives the transcription of these genes.
Given that the Ab/Dkk1 genes are not recognised canonical wnt
targets and as the Dkk1 protein contains N- and C-terminal
cysteine-rich domains, with the C-terminal one being required for
the antagonism of canonical wnt and the N-terminal one possess-
ing wnt-independent activities,46 we generated conditioned
media containing full-length or just the C-terminal or N-terminal
portions of Dkk1. Treating neurons with full-length and C-terminal
conditioned media activated EGR1 (Figure 6a) and FOS expression
(data not shown), whereas N-terminal conditioned media did not.
Primary neurons were then treated with recombinant Dkk1, Dkk2,
Dkk3 and Dkk4 proteins. Dkk4 and Dkk1 induced EGR1 (Figure 6b)
and FOS (data not shown) whereas Dkk2 and Dkk3 did not,
mirroring the abilities of the Dkk1 family to antagonise canonical
wnt.47 This indicates that the Dkk1-dependent transcriptional
effects of Ab are not via a wnt-independent activity of Dkk1, but
that they do involve wnt signalling, possibly via effects on one of
the noncanonical wnt pathways.
To signal via the canonical pathway, the Frizzled (Fzd) family
receptors must interact with their coreceptor proteins, LRP5 or
LRP6.48–50 Dkk1 antagonises canonical wnt by blocking the Fzd–
LRP5/6 interaction and, in doing so, allows Fzd to drive the wnt–
Ca2þ and wnt–planar cell polarity (PCP) pathways.46,51 As PCP
signalling induces gene expression via c-Jun N-terminal kinase
(JNK) and its target, the transcription factor c-Jun,52–54 we looked
for evidence of their activation in primary neurons following
Ab1-42
(olig) and Dkk1 treatments. By western blot analysis, an
increase in activated JNK1 was observed (Figure 6c). Subcellular
fractionation (Figure 6d) and immunofluorescence microscopy
(Figure 6e) demonstrated a concomitant increase in c-Jun activity.
Examining target gene expression by qRT-PCR, the use of
SP600125, an inhibitor with 420-fold selectivity for all three JNK
isoforms over a range of other kinases, blocked induction by
recombinant Dkk1 protein, whereas BI-87G3, an inhibitor more
selective towards JNK2 and JNK3 than JNK1 at the dose used, did
not (Figure 6f). Thus, the transcriptional effects of Ab appear to be
JNK1 dependent and likely because of Dkk1 activation of wnt–PCP
signalling.
Finally, to investigate the relevance of PCP in AD in man, a
list of wnt–PCP pathway component genes was compiled
(Supplementary Figure S1f) and again used to mine the AD
expression data sets.40,42 PCP component genes were significantly
(Po0.0005) altered in AD cases in the combined brain region data
set,42 and in data sets from separate brain regions,40 again most
significantly in AD in mid-temporal gyrus (Po3.2 10 6) and
least in primary visual cortex (Po0.005; Figure 6g), demonstrating
that wnt–PCP signalling is altered in AD brain.
DISCUSSION
We report two novel and important findings regarding a signalling
pathway through which Ab appears to exert its neurotoxic effects.
First, we have uncovered a previously unrecognised effect of Ab
on clusterin protein. Although clusterin has long been implicated
in AD, and has more recently been identified as a risk gene for the
sporadic form of the disease,17 its contribution to disease
pathology has remained enigmatic. We demonstrate that Ab
rapidly targets the clusterin protein, causing its intracellular
accumulation possibly by blocking its exit from neurons. This
effect appears to be specific to Ab, not being observed with other
cytotoxic agents, and is a necessary step in the mechanism by
which Ab exerts its neurotoxic properties. Given that clusterin is
known to bind Ab, an alternative plausible explanation is that Ab–
clusterin complexes form and are internalised and this is
responsible for neurotoxicity.
Second, we demonstrate that Ab-induced changes in clusterin
distribution has acute Dkk1-dependent effects on neuronal gene
transcription and have identified three of its target genes, EGR1,
NAB2 and KLF10, as necessary mediators of Ab-induced neuro-
toxicity and its ability to drive tau phosphorylation. These
transcriptional effects are mediated not by antagonism of the
canonical wnt pathway, as previously thought, but by activation of
noncanonical wnt signalling, specifically the wnt–PCP pathway,
leading to the activation of JNK/c-Jun.
Data derived from multiple animal models and from post-
mortem tissue in humans confirm this pathway is Ab driven and is
not a nonspecific result of cell stress or toxicity. Remarkably, the
pathway appears to be active in DS brain too, again indicating that
it is Ab driven and lending further support to the amyloid cascade
Figure 6. The Ab neurotoxicity pathway is the wnt–planar cell polarity (PCP) pathway. (a) Neurons were treated for 2 h with full-length,
N-Terminal CRD or C-terminal CRD containing conditioned media (CM) and qRT-PCR performed. (b) Neurons were treated as in (c) with
recombinant Dickkopf-1 (Dkk1), Dkk2, Dkk3 and Dkk4 proteins at 800 ngml 1 and expression measured. (c) Neuronal lysates were
immunoblotted for phospho-Thr183/Tyr185-SAPK/JNK and total SAPK/JNK following 3 h of treatments with 3 mM Ab1-42
(olig) or 800 ngml 1
Dkk1. (d) Nuclear fractions were prepared from neurons treated as in (e) and immunoblotted for phospho-Serine63-c-Jun. Equal loading was
determined using anti-H2A.X. (e) Neurons were treated as in (c), fixed and stained for phospho Ser63-c-Jun. Scale bar¼ 10mm. (f ) Neurons
were pre-treated with the c-Jun N-terminal kinase (JNK) inhibitors SP600125 and BI-87G3, each at 10 mM for 3 h, and then with 800 ngml 1
recombinant Dkk1 for 2 h and qRT-PCR was performed. (g) Human brain transcriptomic data were mined with the wnt–PCP pathway
component genes. Significance of differences in Alzheimer’s disease (AD) in the six brain regions examined by Liang et al.40 are shown. CRD,
cysteine rich domain; qRT-PCR, quantitative reverse transcription polymerase chain reaction; SAPK, stress activated protein kinase.
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hypothesis. The mediator of this Ab/clusterin/Dkk1-induced path-
way is p53, reinforcing its emerging role in AD pathogenesis.55
EGR1, the gene most responsive to both Ab and to Dkk1, is a
necessary downstream component of Ab/clusterin/Dkk1-induced
neurotoxicity and tau phosphorylation. In a study of inducible
transcription factors, only Egr1 and c-Jun, which we show likely
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drives EGR1 expression, were found elevated in AD brain.56
Hippocampal expression levels of Egr1 have been shown to
positively correlate with disease progression in AD,57 whereas the
overexpression of EGR1 in rat brain induces tau phosphorylation
via its target, and regulator of cdk5, p35.35 Other Egr1 targets
include the major sporadic AD risk genes APOE17 and CLU.58
Although we found no effect on CLU mRNA with acute Ab
treatments, it remains plausible that chronic Ab exposure could
increase CLU expression, contributing to a pathogenic cycle.
The deleterious synaptic effects of Ab have recently shown to
be Dkk1 dependent15 and attributed to its antagonism of
canonical wnt signalling. Although inhibition of canonical wnt
no doubt contributes to the synaptic effects of Ab, and likely to its
neurotoxicity too, it is worth noting that aberrant Rho signalling
also causes synaptic defects and cognitive impairment59 and that
the wnt–PCP pathway not only drives gene transcription via JNK
but also regulates structural changes via Rho and ROCK.60 Thus,
Ab activation of the wnt–PCP pathway may also contribute to the
synaptic effects of Ab, which now warrants further investigation.
To summarise, we show that Ab-induced neurotoxicity, includ-
ing tau phosphorylation at specific epitopes, is via the CLU-
dependent induction of Dkk1, with Dkk1 then driving wnt–PCP
signalling to increase expression of genes that we have identified
and shown to be necessary mediators of these pathological
processes. In elucidating this, we have positioned a number of
components in a previously unrecognised molecular pathway that
mediates Ab toxicity in rodent primary neurons. These data are
confirmed in vivo in both animal models of amyloidopathy and in
AD and DS brain in humans, adding considerably to the
hypothesis that this pathway contributes to disease pathogenesis.
Together, this further reinforces the idea that it is Ab that drives
AD pathology, a long-standing hypothesis that is now coming
under scrutiny given the failure of drugs aimed at lowering brain
amyloid burden to ameliorate the disease. That this pathway is
dependent on the sporadic AD risk gene, CLU, and that modelling
it in vivo by chronically overexpressing Dkk1 in the mouse brain
gives rise to age-dependent increases in tau phosphorylation, and
cognitive impairment further indicates that the cascade may be
part of the pathway driving AD neuropathology in humans. It also
suggests that blocking the effect of Ab on clusterin or the ability of
Dkk1 to drive wnt–PCP signalling are likely to be fruitful areas in
which novel targets could be identified against which therapeutic
strategies aiming to ameliorate or even halt AD could be
developed.
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